DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United States
  • /
  • Healthcare
Author Program NEWCreate Narrative
FOCL logo

EDAP TMS S.A. Stock Price

NasdaqGM:FOCL Community·US$196.2m Market Cap
  • 4 Narratives written by author
  • 0 Comments on narratives written by author
  • 3 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

FOCL Share Price Performance

US$4.31
1.55 (56.16%)
​
US$8.50
Fair Value
US$4.31
1.55 (56.16%)
49.3% undervalued intrinsic discount
US$8.50
Fair Value
Price US$4.31
AnalystConsensusTarget US$8.50
AnalystHighTarget US$15.00
AnalystLowTarget US$3.00
Fri, 17 Jul 26
Fair ValueUS$8.50
Share Pricen/a

FOCL Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value US$8.5 49.3% undervalued intrinsic discount

Global HIFU Adoption Will Open New Markets

0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value US$15 71.3% undervalued intrinsic discount

HIFU And Focal One Will Transform Care For Aging Patients

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value US$3 43.7% overvalued intrinsic discount

Tariffs And Delays Will Hinder Progress Though Trials Offer Hope

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
FOCL logo
EDAP TMS
59.9% undervalued intrinsic discount

A surgeon's dream

View narrative
LU
LuckyII
Published 7 Jan
Read Narrative
FOCL logo
EDAP TMS
71.3% undervalued intrinsic discount

HIFU And Focal One Will Transform Care For Aging Patients

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 1 Aug
Read Narrative
FOCL logo
EDAP TMS
49.3% undervalued intrinsic discount

Global HIFU Adoption Will Open New Markets

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 17 Jul
Read Narrative
FOCL logo
EDAP TMS
43.7% overvalued intrinsic discount

Tariffs And Delays Will Hinder Progress Though Trials Offer Hope

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 23 Jun
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

LU
FOCL logo

A surgeon's dream

Fair Value: US$10.74 59.9% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
FOCL logo

FOCL: Rising Ultrasound Adoption And New Indications Will Support Future Re Rating

Fair Value: US$15 71.3% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystConsensusTarget
FOCL logo

FOCL: Prostate Cancer Ultrasound Adoption Will Drive Longer Term Upside

Fair Value: US$8.5 49.3% undervalued intrinsic discount
2 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Good value with low risk.

3 Risks
2 Rewards
View Full Analysis

EDAP TMS S.A. Key Details

US$79.3m

Revenue

US$44.0m

Cost of Revenue

US$35.3m

Gross Profit

US$74.4m

Other Expenses

-US$39.1m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.85
44.49%
-49.32%
-1,237.4%
View Full Analysis

About FOCL

Founded
1979
Employees
289
CEO
Ryan Rhodes
WebsiteView website
investor.focalone.com

EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. In addition, the company manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters; and sells spare parts and disposables, such as electrodes. Further, it markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales channels, and third-party distributors and agents. The company serves academic, public, and private hospitals, as well as clinics. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop clinical workflows combining PSMA PET imaging and Focal One Robotic HIFU for prostate cancer. EDAP TMS S.A. was incorporated in 1979 and is headquartered in Vaulx-en-Velin, France.

Recent FOCL News & Updates

Recent updates

No updates

EDAP TMS S.A. Competitors

DCTH logo

Delcath Systems

Symbol: NasdaqCM:DCTH
Market cap: US$571.1m
FLGT logo

Fulgent Genetics

Symbol: NasdaqGM:FLGT
Market cap: US$533.0m
CERS logo

Cerus

Symbol: NasdaqGM:CERS
Market cap: US$532.0m
MDRX logo

Veradigm

Symbol: OTCPK:MDRX
Market cap: US$523.3m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide